Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) just unveiled an announcement.
Jacobio Pharmaceuticals Group Co., Ltd. has announced that the Phase I/IIa clinical study results of its KRAS G12C inhibitor glecirasib, combined with the SHP2 inhibitor JAB-3312, have been published in The Lancet Respiratory Medicine. This study, conducted in China with 171 patients, showed promising results with a 71% objective response rate and a 12.2-month median progression-free survival in untreated non-small cell lung cancer patients. The combination therapy, which is chemotherapy-free, is now in Phase III trials and could potentially become the first SHP2-containing combination therapy to gain global approval, positioning Jacobio as a competitive player in the oncology treatment landscape.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a pharmaceutical company focused on developing innovative products and solutions to improve patient health. The company specializes in novel molecular targets across six major signaling pathways, including KRAS, immune checkpoints, and tumor metabolism. Jacobio aims to be a global leader in drug research and development, with R&D centers in Beijing, Shanghai, and Boston.
Average Trading Volume: 8,011,787
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.31B
For detailed information about 1167 stock, go to TipRanks’ Stock Analysis page.